Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. more
Time Frame | INMB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.06% | -2.27% | -0.57% |
1-Month Return | -16.96% | -3.96% | 1.21% |
3-Month Return | -13% | -9.7% | 7.57% |
6-Month Return | -47.69% | -3.37% | 11.45% |
1-Year Return | -54.93% | 3.71% | 28.48% |
3-Year Return | -58.15% | 3.8% | 29.52% |
5-Year Return | -3.65% | 39.78% | 90.66% |
10-Year Return | -40.55% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 77.69M | 10.92K | 181.00K | 374.00K | 155.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.01,"profit":true},{"date":"2021-12-31","value":0.23,"profit":true},{"date":"2022-12-31","value":0.48,"profit":true},{"date":"2023-12-31","value":0.2,"profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 77.69M | 10.92K | 181.00K | 374.00K | 155.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.01,"profit":true},{"date":"2021-12-31","value":0.23,"profit":true},{"date":"2022-12-31","value":0.48,"profit":true},{"date":"2023-12-31","value":0.2,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 9.30M | 12.24M | 29.33M | 26.32M | 29.90M | [{"date":"2019-12-31","value":31.1,"profit":true},{"date":"2020-12-31","value":40.94,"profit":true},{"date":"2021-12-31","value":98.12,"profit":true},{"date":"2022-12-31","value":88.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (7.76M) | (12.23M) | (29.15M) | (25.95M) | (29.74M) | [{"date":"2019-12-31","value":-775600100,"profit":false},{"date":"2020-12-31","value":-1222767600,"profit":false},{"date":"2021-12-31","value":-2915300000,"profit":false},{"date":"2022-12-31","value":-2595100000,"profit":false},{"date":"2023-12-31","value":-2974100000,"profit":false}] |
Total Non-Operating Income/Expense | 155.38K | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (7.68M) | (12.10M) | (30.34M) | (27.30M) | (30.01M) | [{"date":"2019-12-31","value":-767831300,"profit":false},{"date":"2020-12-31","value":-1209915900,"profit":false},{"date":"2021-12-31","value":-3034000000,"profit":false},{"date":"2022-12-31","value":-2729900000,"profit":false},{"date":"2023-12-31","value":-3000800000,"profit":false}] |
Income Taxes | 1.46M | (128.52K) | 1.19M | 1.35M | (29.74M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-8.78,"profit":false},{"date":"2021-12-31","value":81.06,"profit":true},{"date":"2022-12-31","value":92.06,"profit":true},{"date":"2023-12-31","value":-2031.06,"profit":false}] |
Income After Taxes | (9.14M) | - | - | - | - | [{"date":"2019-12-31","value":-914262500,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (7.68M) | (12.10M) | (30.34M) | (25.95M) | (27.43M) | [{"date":"2019-12-31","value":-767831300,"profit":false},{"date":"2020-12-31","value":-1209915900,"profit":false},{"date":"2021-12-31","value":-3034000000,"profit":false},{"date":"2022-12-31","value":-2595100000,"profit":false},{"date":"2023-12-31","value":-2743300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (9.14M) | (12.10M) | (30.34M) | (28.65M) | (30.01M) | [{"date":"2019-12-31","value":-914262500,"profit":false},{"date":"2020-12-31","value":-1209915900,"profit":false},{"date":"2021-12-31","value":-3034000000,"profit":false},{"date":"2022-12-31","value":-2864700000,"profit":false},{"date":"2023-12-31","value":-3000800000,"profit":false}] |
EPS (Diluted) | (0.89) | (1.01) | (1.86) | (1.52) | (1.67) | [{"date":"2019-12-31","value":-89,"profit":false},{"date":"2020-12-31","value":-101,"profit":false},{"date":"2021-12-31","value":-186,"profit":false},{"date":"2022-12-31","value":-152,"profit":false},{"date":"2023-12-31","value":-167,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
INMB | |
---|---|
Cash Ratio | 2.43 |
Current Ratio | 2.59 |
Quick Ratio | 2.70 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
INMB | |
---|---|
ROA (LTM) | -44.97% |
ROE (LTM) | -98.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
INMB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.73 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
INMB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2771.55 |
P/B | 3.01 |
Price/FCF | NM |
EV/R | 2042.06 |
EV/Ebitda | NM |
INmune Bio Inc (INMB) share price today is $4.75
Yes, Indians can buy shares of INmune Bio Inc (INMB) on Vested. To buy INmune Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INMB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of INmune Bio Inc (INMB) via the Vested app. You can start investing in INmune Bio Inc (INMB) with a minimum investment of $1.
You can invest in shares of INmune Bio Inc (INMB) via Vested in three simple steps:
The 52-week high price of INmune Bio Inc (INMB) is $14.74. The 52-week low price of INmune Bio Inc (INMB) is $4.45.
The price-to-earnings (P/E) ratio of INmune Bio Inc (INMB) is
The price-to-book (P/B) ratio of INmune Bio Inc (INMB) is 3.01
The dividend yield of INmune Bio Inc (INMB) is 0.00%
The market capitalization of INmune Bio Inc (INMB) is $116.41M
The stock symbol (or ticker) of INmune Bio Inc is INMB